Athira Pharma (NASDAQ:LONA) Rating Lowered to “Sell” at Wall Street Zen

Athira Pharma (NASDAQ:LONA) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

LONA has been the topic of several other reports. Mizuho upgraded shares of Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 price objective on the stock in a research note on Thursday, February 19th. Cantor Fitzgerald initiated coverage on Athira Pharma in a report on Thursday. They set an “overweight” rating for the company. Finally, Weiss Ratings assumed coverage on Athira Pharma in a research report on Wednesday, February 11th. They set a “sell (d-)” rating on the stock. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Athira Pharma Trading Up 0.2%

Shares of Athira Pharma stock opened at $5.63 on Friday. The company has a market cap of $22.18 million, a PE ratio of -0.58 and a beta of 2.67. Athira Pharma has a 12-month low of $2.20 and a 12-month high of $8.36.

Athira Pharma Company Profile

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.